This combined delivery system activated DCs in situ and cross-primed tumor-reactive CD8+ T-cell responses, leading to tumor inhibition in a poorly immunogenic TNBC mouse xenograft model and patient-derived tumor organoids. The gene discussed is CD8A; the disease is neoplasm.